Synapse Open Synapse
Biology

Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial

Nature Medicine · · 34 min read

The OUTSTAND-1 trial showed that once-daily oral small-molecule GLP-1 receptor agonist safiglipron reduced HbA1c by up to 1.45% versus placebo over 32 weeks in people with type 2 diabetes without glucose-lowering medication while body weight effects were modest.

Latest from Nature Medicine